Showing 21-30 of 70 results for "".
- Two-Year Data Confirm Benefits, Safety of Tremfya in PsA and PsOhttps://practicaldermatology.com/news/two-year-data-confirm-benefits-safety-of-tremfya-is-psa-and-pso/2460722/Long-term data from the Phase 3 DISCOVER-2 study show continued benefit for Tremfya (guselkumab) for up to two years in adults with active psoriatic arthritis. Previous data demonstrated skin clearance, joint symptom relief, and safety for Tremfya through 24 weeks and one year (Week 52) in adults w…
- Galderma and Aklief Unveil "Me Being Me" Campaign, Survey Results on Acne Zoom Burdenhttps://practicaldermatology.com/news/galderma-and-aklief-unveil-me-being-me-campaign-survey-results-on-acne-zoom-burden/2460703/Galderma Laboratories, L.P. and Aklief (trifarotene) Cream, 0.005% are launching Me Being Me, a new consumer campaign that was crafted in response to today’s increasingly digital-focused world. The campaign is designed to inspire those living with acne to feel confident in their own skin by sharin…
- COVID-19, the Stock Market, and Dermatologyhttps://practicaldermatology.com/news/covid-19-the-stock-market-and-dermatology/2460688/By Amylee Martin, BS, Akshitha Thatiparthi, BS, Jeffrey Liu, BS, Jashin J. Wu, MD Novel coronavirus, COVID-19, is not only a major public health threat but has also impacted the economy. Due to the pandemic, experts predict a 0.5% decrease in the global gross domestic product growth during 20…
- Sciton Rolls Out “You Deserve Better, You Deserve Sciton” Ad Campaignhttps://practicaldermatology.com/news/sciton-rolls-out-you-deserve-better-you-deserve-sciton-ad-campaign/2460620/Sciton Inc. is launching its new “You Deserve Better, You Deserve Sciton” advertising series to coincide with the holiday season. The series of five ads launched on Black Friday will run through the Spring with a focus on Sciton’s technologies. The new ad campaign will reach consumers on Facebook,…
- Research Identifies Long-Term Benefits of Incorporating Ceramides into Baby Skincarehttps://practicaldermatology.com/news/research-identifies-long-term-benefits-of-incorporating-ceramides-into-baby-skincare/2460612/Using ceramide-infused products on baby skin may have long-term benefits lasting into adulthood, according to a newly published study in the Journal of Drugs in Dermatology. Beyond neonatal and infant development, the research showed that incorporating moisturizers and cleansers with ceramides ca…
- AAD Names Dr. Sacharitha Bowers a Patient Care Hero for Helping Address Disparities in Care Due to COVID-19https://practicaldermatology.com/news/aad-names-dr-sacharitha-bowers-a-patient-care-hero-for-helping-address-disparities-in-care-due-to-covid-19/2460610/Sacharitha Bowers, MD, FAAD, is an American Academy of Dermatology (AAD) Patient Care Hero for her role in addressing disparities in care related to COVID-19 in Springfield, Ill. Leveraging years of relationship-building with local organizations and community members, the Southern Illinois Univers…
- Where is the Hydroquinone? Regulatory Change Hinders Accesshttps://practicaldermatology.com/news/where-is-the-hydroquinone-regulatory-change-hinders-access/2460586/Changes to FDA regulations implemented as part of the CARES Act this spring have left dermatologists and their patients scrambling to access hydroquinone. Although access is hindered, it is not cut off. “I think most people at this point are familiar with the CARES Act. What they may not realize i…
- FDA Oks Endo's Anti-Cellulite Injectablehttps://practicaldermatology.com/news/fda-oks-endos-anti-cellulite-injectable/2460454/The FDA has given its nod to an entirely new way to address cellulite. Endo Aesthetic’s Qwo (collagenase clostridium histolyticum-aaes) is the first injectable treatment for moderate to severe cellulite of the buttocks in adult women. When fat in cellulite-prone areas swells and expands, the septa…
- Positive Top Line Results from Second Phase 3 Study of Abrocitinib for Atopic Dermatitishttps://practicaldermatology.com/news/positive-top-line-results-from-second-phase-3-study-of-abrocitinib-for-atopic-dermatitis-1/2460159/Pfizer Inc. shared positive top-line results from a second Phase 3 pivotal study evaluating the efficacy and safety of its investigational oral Janus kinase 1 (JAK1) inhibitor, abrocitinib, in patients aged 12 and older with moderate to severe atopic dermatitis (AD). This is the second monotherapy …
- Good Science Beauty Skincare Line Makes NYC Debuthttps://practicaldermatology.com/news/good-science-beauty-skincare-line-makes-nyc-debut/2460028/Spring always heralds the arrival many new skincare lines and products, and one of this season’s standouts may be Good Science Beauty, a line of six collagen-boosting products delivered via Silicon+ technology. The new skincare line was recently unveiled to members of the media at an all-day beaut…